Eli Lilly (LLY): Расширение сотрудничества Gate Bioscience в области труднодоступных для лекарств белков

Движение акции сверх рынка по сессиям

В обычных днях (σ): движение LLY сверх её обычной связи с QQQ. Тёмные столбцы — дни с событием сюжета; R — окно отчёта.

Хронология

События сюжета в порядке прихода в нашу ленту, время нью-йоркское. Событие — один факт; показан первый заголовок и до трёх других сообщений о нём.

1. 05.10 08:04

   GNWGate Bioscience расширяет партнёрство с Lilly для работы с труднодоступными белками

   YF08:41Gate Bioscience расширяет сделку с Lilly по разработке лекарств на сумму более $870 млн

   MF11:46Эта акция малой капитализации объявила о сделке с Eli Lilly, после чего её акции удвоились

   YF12:11Lilly возвращается к Gate Bioscience: сделка на сумму до $870 млн

   всего сообщений: 9

Оценки по вечерам

Каждый вечер в 22:00 UTC, пока у сюжета были новости за последние три дня. Модель видела только события, пришедшие к этому времени, и дневные движения акции сверх рынка.

Company: LLY (Eli Lilly). Now: 2026-10-07 22:00 UTC (Wednesday).
Storyline: Gate Bioscience collaboration expansion for difficult-to-drug proteins
Chronology (UTC):
- 10-05 12:04 Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins (+5 similar)
Stock move beyond the market by session, in typical days (sigma): 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0, 10-06 +0.8, 10-07 +1.6

Company: LLY (Eli Lilly). Now: 2026-10-06 22:00 UTC (Tuesday).
Storyline: Gate Bioscience collaboration expansion for difficult-to-drug proteins
Chronology (UTC):
- 10-05 12:04 Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins (+5 similar)
Stock move beyond the market by session, in typical days (sigma): 09-29 -0.0, 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0, 10-06 +0.8

Company: LLY (Eli Lilly). Now: 2026-10-05 22:00 UTC (Monday).
Storyline: Gate Bioscience collaboration expansion for difficult-to-drug proteins
Chronology (UTC):
- 10-05 12:04 Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins (+5 similar)
Stock move beyond the market by session, in typical days (sigma): 09-28 +0.1, 09-29 -0.0, 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0

Как модель собирала сюжет

Для каждого события модель видела активные сюжеты компании и выбирала: продолжить один из них, начать новый или считать событие разовым.

1. 05.10 08:04

   Новый сюжет · Gate Bioscience расширяет партнёрство с Lilly для работы с труднодоступными белками

   Вопрос и ответ · DeepSeek-V4-Flash, thinking high · s2

   Company: LLY (Eli Lilly)
   New event (10-05 12:04 UTC): Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins
     also reported: Gate Bioscience expands Lilly drug discovery deal worth more than $870 million
     also reported: This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled
   
   Storylines:
   1. Foundayo demonstrates cardiovascular safety in large type 2 diabetes trial
      first (09-30 22:02): Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
      latest (10-02 22:46): Eli Lilly’s Foundayo delivers diabetes surprise in late-stage study
   2. Jaypirca FDA approval expansion for CLL/SLL
      first (10-02 19:07): Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
   3. Lilly takes over Milan facility in obesity battle with Novo
      first (10-02 08:20): Lilly Upstages Novo in Fresh Obesity Battle by Taking Over Milan
   4. Lilly dispute with German health policy
      first (10-02 07:01): “My Trust Is Destroyed” Eli Lilly Boss Settles Accounts With German Health Policy - HB
   5. Lilly exits Foghorn collaboration on cancer drug
      first (10-01 12:08): Foghorn plunges as Lilly exits collaboration
      latest (10-01 16:21): Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
   6. EloraTZP Phase 2 success in obesity and type 2 diabetes
      first (09-30 14:15): Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
      latest (09-30 14:21): Experimental Lilly combination drug tops Zepbound in weight-loss trial
   7. EBGLYSS Phase 3b success in hand and foot atopic dermatitis
      first (09-30 12:05): New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
   8. Retatrutide phase 3 results show substantial weight loss and A1C reduction
      first (09-29 22:02): Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
      latest (09-30 00:12): ELI LILLY SAYS THE TRIPLE AGONIST ALSO REDUCED A1C IN PEOPLE WITH OBESITY AND TYPE 2 DIABETES, WITH A BIOLOGICS LICENCE APPLICATION PLANNED FOR Q1 2027.
   9. Foundayo shows superiority over oral semaglutide in diabetes analysis
      first (09-29 07:01): Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
      latest (09-29 16:14): Lilly Stock Drops Lowwer Foundayo Claims an Oral Edge
   10. Zepbound shows greater weight loss than Wegovy in indirect comparison
      first (09-29 11:02): Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
   11. Novo Nordisk trial results show cardiovascular edge over Lilly's tirzepatide
      first (09-28 18:45): Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape?
   12. Lilly U.S. manufacturing expansion
      first (09-21 21:40): Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
      latest (09-28 14:40): He Will Switch Contractors to Help Build Eli Lilly’s $6.5 Billion Plant. Two W-2s Could Put $2,821 in Social Security Taxes Back in His Pocket
   
   → {"story": 0, "title": "Gate Bioscience collaboration expansion for difficult-to-drug proteins"}